Tumor, Benign clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
open to eligible people ages 22 years and up
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.
at UCLA
Our lead scientists for Tumor, Benign research studies include Brian Shuch, MD.
Last updated: